Research
Hormonal
Lorcaserin (10 mg twice daily) provides sustained weight loss without increasing the rate of major cardiovascular events compared to placebo in high-risk overweight or obese patients.
If you are overweight or obese and have heart disease or risk factors, taking lorcaserin (10mg twice daily) along with diet and exercise helps you lose more weight than diet and exercise alone, without increasing your risk of heart attack or stroke compared to just doing diet and exercise.
StrongSupportsVERY_HIGH confidence
In a high-risk population of overweight or obese patients, lorcaserin facilitated sustained weight loss without a higher rate of major cardiovascular events than that with placebo.
Why this rating
Large-scale, randomized, double-blind, placebo-controlled trial (CAMELLIA-TIMI 61) with 12,000 patients.
Source
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Erin A. Bohula et al. · New England Journal of Medicine · 2018
DOI 10.1056/nejmoa1808721
rct · n=12000Cited 263×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →